ALLIANCES (Pfizer) (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
		Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 7,945	$ 6,007	$ 6,273	$ 5,920	$ 5,973	$ 5,691	$ 5,704	$ 5,193	$ 26,145	$ 22,561	$ 20,776
Cost of Goods and Services Sold	[1]									8,078	6,467	6,014
Other Nonoperating Income (Expense)										938	(854)	(1,685)
Receivables		7,685				5,747				7,685	5,747
Accounts payable		2,445				1,892				2,445	1,892
Eliquis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										7,929	6,438	4,872
Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Receivables		247				220				247	220
Accounts payable		922				786				922	786
Deferred income		355				410				355	410
Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										10,541	9,006	7,879
Cost of Goods and Services Sold										4,169	3,439	2,718
Other Nonoperating Income (Expense)										(60)	(67)	(46)
Receivables		347				395				347	395
Accounts payable		1,026				904				1,026	904
Deferred income		$ 431				$ 491				431	491
Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										7,929	6,438	4,872
Cost of Goods and Services Sold										3,745	3,078	2,314
Other Nonoperating Income (Expense)										$ (55)	(55)	(55)
Collaborative Arrangement [Member] | Pfizer [Member] | Eliquis [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum percentage of reimbursement for development costs from alliance partner		50.00%								50.00%
Maximum percentage of reimbursement for development costs from alliance partner		60.00%								60.00%
Total upfront, milestone and other licensing payments received to date		$ 884								$ 884
Net product sales [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										25,174	21,581	19,258
Net product sales [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										9,944	8,359	6,917
Net product sales [Member] | Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										7,711	6,329	4,808
Collaborative Arrangement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										597	647	962
Collaborative Arrangement [Member] | Collaborative Arrangement [Member] | Pfizer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues										$ 218	$ 109	$ 64

[1] Excludes amortization of acquired intangible assets.